Literature DB >> 10564389

Clinicopathological analysis of 501 non-Hodgkin's lymphomas in Korea according to the revised European-American classification of lymphoid neoplasms.

S S Lee1, K J Cho, C W Kim, Y K Kang.   

Abstract

AIMS: The clinical relevance of the Revised European-American Classification of Lymphoid Neoplasms (REAL) is still debated. To test the clinical validity of the REAL classification in Korea, where the incidence of T-cell lymphoma is higher, we investigated the clinicopathological features of non-Hodgkin's lymphoma (NHL) from Korea Cancer Center Hospital. METHODS AND
RESULTS: Five hundred and one patients with NHL were reclassified according to the REAL classification and clinicopathologically analysed. Immunophenotypically, B-cell lymphoma accounted for 67.9% and T- and NK-cell type for 30.5%. Approximately 48.5% of cases were forms of diffuse large B-cell lymphoma (DLBCL), while only 5.4% were follicular lymphoma. Peripheral T-cell lymphoma unspecified (PTCL-U; 10.8%) and angiocentric lymphomas (11.8%) comprised the majority of T-cell lymphomas. Most of the angiocentric lymphomas presented with localized nasal/nasopharyngeal or tonsillar primaries. All peripheral T-cell lymphomas (PTCL) showed a significantly low overall survival compared to DLBCL (P = 0.02, log rank). Overall survival rates for DLBCL and PTCL-U were also significantly different (P = 0.0043, log rank), though for DLBCL and angiocentric lymphoma there was no significant difference (P = 0.2142, log rank). Angiocentric lymphoma, however, was characterized by a shorter median survival time than DLBCL (54 months vs. 96 months). Among DLBCL patients according to the REAL classification, overall survival was significantly better in nonimmunoblastic type (intermediate-grade, WF-F,G) as compared to large cell immunoblastic type (high-grade, WF-H) (log rank, P < 0.001). The morphological distinction of the immunoblastic and nonimmunoblastic among DLBCL of the REAL classification bears significant prognostic relevance worthy of further consideration.
CONCLUSION: We conclude that lineage assignment (T vs. B) in the REAL classification is a clinically important distinction, but that it is necessary to subdivide the broad category of DLBCL.

Entities:  

Mesh:

Year:  1999        PMID: 10564389     DOI: 10.1046/j.1365-2559.1999.00721.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  6 in total

Review 1.  [Malignant lymphomas of the liver: new diagnostic algorithms].

Authors:  T Longerich; P Schirmacher; H P Dienes; H Stein; C Loddenkemper
Journal:  Pathologe       Date:  2006-07       Impact factor: 1.011

2.  CD5+ diffuse large B-cell lymphoma consists of germline cases and hypermutated cases in the immunoglobulin heavy chain gene variable region.

Authors:  Naoya Nakamura; Shigeo Nakamura; Motoko Yamaguchi; Ryo Ichinohasama; Tadashi Yoshino; Tetsuo Kuze; Yoshikazu Sasaki; Sachiko Yoshida; Masafumi Abe
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

3.  Peripheral T-cell lymphoma in the neck: CT findings of lymph node involvement.

Authors:  J W Choi; S S Kim; E Y Kim; M Heran
Journal:  AJNR Am J Neuroradiol       Date:  2006-05       Impact factor: 3.825

4.  Investigation of T-cell receptor-gamma gene rearrangement in gastrointestinal lymphomas by PCR-SSCP analysis.

Authors:  Xi-Qun Han; Li He; Lan-Ying Shong; Hui-Yong Jiang; Mei-Gang Zhu; Tong Zhao
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

5.  Malignant lymphoma in Jordan: a retrospective analysis of 347 cases according to the World Health Organization classification.

Authors:  William J Haddadin
Journal:  Ann Saudi Med       Date:  2005 Sep-Oct       Impact factor: 1.526

6.  The clinicopathologic features and response to treatment of patients with Nonhodgkin Lymphoma: A single-center experiment in Turkey.

Authors:  Rahsan Yildirim; Gulden Sincan
Journal:  Pak J Med Sci       Date:  2019 Jan-Feb       Impact factor: 1.088

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.